Health-related QoL in ipilimumab treated advanced melanoma survivors

Health-related QoL in ipilimumab treated advanced melanoma survivors

Publication date: Nov 06, 2019

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the health-related quality of life of advanced melanoma survivors treated with ipilimumab (CTLA-4 immune checkpoint inhibition) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Concepts Keywords
Amsterdam Checkpoint inhibitor
Barcelona Health
Brain Cancer treatments
Christian Ipilimumab
Cognitive Bristol-Myers Squibb
Cohort Clinical medicine
DDE Medicine
Ipilimumab Immune system
Melanoma Related advanced melanoma
Mets Advanced melanoma
Netherlands Melanoma
PhD Immune checkpoint
Spain

Semantics

Type Source Name
drug DRUGBANK Ipilimumab
disease MESH melanoma
disease DOID melanoma
pathway BSID Melanoma
gene UNIPROT PDC
disease MESH Cancer
disease DOID Cancer
gene UNIPROT CTLA4

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *